PainChek Ltd
ASX:PCK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PainChek Ltd
Revenue
PainChek Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PainChek Ltd
ASX:PCK
|
Revenue
AU$3.4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
4DMedical Ltd
ASX:4DX
|
Revenue
AU$5.8m
|
CAGR 3-Years
61%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Revenue
$56.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Pro Medicus Ltd
ASX:PME
|
Revenue
AU$248.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
33%
|
CAGR 10-Years
27%
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Revenue
AU$48.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
86%
|
|
|
A
|
Artrya Ltd
ASX:AYA
|
Revenue
AU$28k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PainChek Ltd
Glance View
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.
See Also
What is PainChek Ltd's Revenue?
Revenue
3.4m
AUD
Based on the financial report for Dec 31, 2025, PainChek Ltd's Revenue amounts to 3.4m AUD.
What is PainChek Ltd's Revenue growth rate?
Revenue CAGR 5Y
70%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for PainChek Ltd have been 34% over the past three years , 70% over the past five years .
